|
[1]
|
W. K. de Jong, J. L. G. Blaauwgeers, M Schaapveld, et al., “Thymic Epithelial Tumours: A Population-Based Study of the Incidence, Diagnostic Procedures and Therapy,” European Journal of Cancer, Vol. 44, No. 1, 2008, pp 123-130. doi:10.1016/j.ejca.2007.11.004
|
|
[2]
|
P. Engel, A. Marx and H. K. Müller-Hermelink, “Thymic tumours in Denmark. A Retrospective Study of 213 Cases from 1970-1993,” Pathology—Research and Practice, Vol. 195, No. 8, 1999, pp. 565-570.
doi:10.1016/S0344-0338(99)80006-5
|
|
[3]
|
J. V. Souadjan, P Enriquez, M. N. Silverstein and J. M. Pépin, “The Spectrum of Diseases Associated with Thymoma. Coincidence or Syndrome?” Archives of Internal Medicine, Vol. 134, No. 2, 1974, pp. 374-379.
doi:10.1001/archinte.1974.00320200184029
|
|
[4]
|
E. N. Dessypris, “The Biology of Pure Red Cell Aplasia,” Semin Hematol, Vol. 28, No. 4, 1991, pp. 275-284.
|
|
[5]
|
P. E. Tarr, M. C. Sneller, L. J. Mechanic, et al., “Infections in Patients with Immunodeficiency with Thymoma (Good Syndrome). Report of 5 Cases and Review of the Literature,” Medicine (Baltimore), Vol. 80, No. 2, 2001, pp .123-133. doi:10.1097/00005792-200103000-00005
|
|
[6]
|
T. Y. Eng, C. D. Fuller, J. Jagirdar, et al., “Thymic Carcinoma: State of the Art Review,” International Journal of Radiation Oncology, Biology, Physics, Vol. 59, No. 3, 2004, pp. 654-664. doi:10.1016/j.ijrobp.2003.11.021
|
|
[7]
|
J. E. Lewis, M. R. Wick, B. W. Scheithauer, et al., “Thymoma. A Clinicopathologic Review,” Cancer, Vol. 60, No. 11, 1987, pp. 2727-2743.
doi:10.1002/1097-0142(19871201)60:11<2727::AID-CNCR2820601125>3.0.CO;2-D
|
|
[8]
|
F. C. Detterbeck, “Clinical Value of the WHO Classification System of Thymoma,” The Annals of Thoracic Surgery, Vol. 81, No. 6, 2006, pp. 2328-2334.
doi:10.1016/j.athoracsur.2005.11.067
|
|
[9]
|
A. Masaoka, Y. Monden, K. Nakahara and T. Tanicka, “Follow-Up Study of Thymomas with Special Reference to Their Clinical Stages,” Cancer, Vol. 48, No. 11, 1981, pp. 2485-2492.
doi:10.1002/1097-0142(19811201)48:11<2485::AID-CNCR2820481123>3.0.CO;2-R
|
|
[10]
|
K. Kondo and Y. Monden, “Therapy of Thymic Epithelial Tumors: A Clinical Study of 1320 Patients from Japan,” The Annals of Thoracic Surgery, Vol. 76, No. 3, 2003, pp 878-884. doi:10.1016/S0003-4975(03)00555-1
|
|
[11]
|
“NCCN Clinical Practice Guidelines in Oncology,” 2010.
http://www.nccn.org/professionals/physician_gls/PDF/thymic.pdf
|
|
[12]
|
P. Str?bel, R. Bargou, A. Wolff, et al., “Sunitinib in Metastatic Thymic Carcinomas: Laboratory Findings and Initial Clinical Experience,” British Journal of Cancer, Vol. 103, No. 2, 2010, pp. 196-200.
doi:10.1038/sj.bjc.6605740
|
|
[13]
|
G. Bisagni, G. Rossi, A. Cavazza, et al., “Long lasting Response to the Multikinase Inhibitor Bay 43-9006 (Sorafenib) in a Heavily Pretreated Metastatic Thymic Carcinoma,” Journal of Thoracic Oncology, Vol. 4, No. 6, 2009, pp. 773-775. doi:10.1097/JTO.0b013e3181a52e25
|
|
[14]
|
X. F. Li, Q. Chen, W. X. Huang and Y. B. Ye, “Response to Sorafenib in Cisplatin-Resistant Thymic Carcinoma: A Case Report,” Medical Oncology, Vol. 26, No. 2, 2009, pp 157-160. doi:10.1007/s12032-008-9100-0
|
|
[15]
|
F. C. Detterbeck and A. M. Parsons, “Thymic Tumors,” The Annals of Thoracic Surgery, Vol. 77, No. 5, 2004, pp. 1860-1869. doi:10.1016/j.athoracsur.2003.10.001
|
|
[16]
|
E. Davenport and R. A. Malthaner, “The Role of Surgery in the Management of Thymoma: A Systematic Review,” The Annals of Thoracic Surgery, Vol. 86, No. 2, 2008, pp. 673-684. doi:10.1016/j.athoracsur.2008.03.055
|
|
[17]
|
P. Str?bel, A. Bauer, B. Puppe, et al., “Tumor Recurrence and Survival in Patients Treated for Thymomas and Thymic Squamous Cell Carcinomas: A Retrospective Analysis,” Journal of Clinical Oncology, Vol. 22, No. 8, 2004, pp 1501-1509. doi:10.1200/JCO.2004.10.113
|
|
[18]
|
J.-F. Regnard, P. Magdeleinat, C. Dromer, et al., “Prognostic Factors and Long-Term Results after Thymoma Resection: A Series of 307 Patients,” The Journal of Thoracic and Cardiovascular Surgery, Vol. 112, No. 2, 1996, pp. 376-384. doi:10.1016/S0022-5223(96)70265-9
|
|
[19]
|
M. Okumura, S. Miyoshi, Y. Takeuchi, et al., “Results of Surgical Treatment of Thymomas with Special Reference to the Involved Organs,” The Journal of Thoracic and Cardiovascular Surgery, Vol. 117, No. 3, 1999, pp. 605613. doi:10.1016/S0022-5223(99)70343-0
|
|
[20]
|
T. Murakawa, J. Nakajima, T. Kohno, et al., “Results from Surgical Treatment for Thymoma. 43 Years of Experience,” The Journal of Thoracic and Cardiovascular Surgery, Vol. 48, No. 2, 2000, pp. 89-95.
doi:10.1007/BF03218097
|
|
[21]
|
C. B. Falkson, A. Bezjak, G. Darling, et al., “The Management of Thymoma: A Systematic Review and Practice Guideline,” Journal of Thoracic Oncology, Vol. 4, No. 7, 2009, pp. 911-919. doi:10.1097/JTO.0b013e3181a4b8e0
|
|
[22]
|
J. L. Port and R. J. Ginsberg, “Surgery for the Thymoma,” Chest Surgery Clinics of North America, Vol. 11, No. 2, 2001, pp. 421-437.
|
|
[23]
|
Y. J. Cheng, J. S. Hsu and E. L. Kao, “Characteristics of Thymoma Successfully Resected by Videothorascopic Surgery,” Surgery Today, Vol. 37, No. 3, 2007, pp. 192196. doi:10.1007/s00595-006-3383-6
|
|
[24]
|
A. Toker, J. Sonett, M. Zielinski, et al, “Standard Terms, Definitions and Policies for Minimally Invasive Resection of Thymoma,” Journal of Clinical Oncology, Vol. 6, 2011, pp. S1739-1748.
|
|
[25]
|
J. A. Forquer, N. Rong, A. J. Fakiris, et al., “Postoperative Radiotherapy after Surgical Resection of Thymoma: Differing Roles in Localized and Regional Diseases,” International Journal of Radiation Oncology, Biology, Physics, Vol. 76, No. 2, 2010, pp. 440-445.
doi:10.1016/j.ijrobp.2009.02.016
|
|
[26]
|
K. Ogawa, T. Uno, T. Toita, et al., “Postoperative Radiotherapy for Patients with Completely Resected Thymoma: A Multi-Institutional, Retrospective Review of 103 Patients,” Cancer, Vol. 94, No. 5, 2002, pp. 1405-1413.
doi:10.1002/cncr.10373
|
|
[27]
|
T. Utsumi, H. Shiono, Y. Kadota, et al., “Postoperative Radiation Therapy after Complete Resection of Thymoma Has Little Impact on Survival,” Cancer, Vol. 115, No. 23, 2009, pp. 5413-5420. doi:10.1002/cncr.24618
|
|
[28]
|
S. Kaseda, H. Horinouchi, R. Kato, et al., “Treatment of Invasive Thymoma Using Low Dose and Extended-Field Irradiation Including Hemi-Thorax or Whole-Thorax,” Kyobu Geka, Vol. 46, No. 1, 1993, pp. 31-40.
|
|
[29]
|
D. Gomez, R. Komaki, J. Yu, H. Ikushima and A. Bezjak, “Radiation Therapy Definitions and Reporting Guidelines for Thymic Malignancies,” Journal of Thoracic Oncology, Vol. 6, No. 7, 2011, pp. S1743-S1748.
doi:10.1097/JTO.0b013e31821ea60c
|
|
[30]
|
W. J. Curran, M. J. Kornstein, J. J. Brooks, et al., “Invasive Thymoma: The Role of Mediastinal Irradiation,” Journal of Clinical Oncology, Vol. 6, No. 11, 1988, pp. 1722-1727.
|
|
[31]
|
E. S. Kim, J. B. Putnam, R. Komaki, et al., “Phase II Study of a Multidisciplinary Approach with Induction Chemotherapy, Followed by Surgical Resection, Radiation Therapy and Consolidation Chemotherapy for Unresectable Malignant Thymomas: Final Report,” Lung Cancer, Vol. 44, No. 3, 2004, pp. 369-379.
doi:10.1016/j.lungcan.2003.12.010
|
|
[32]
|
A. Berruti, P. Borasio, A. Gerbino, et al., “Primary Chemotherapy with Adriamycin, Cisplatin, Vincristine and Cyclophosphamide in Locally Advanced Thymomas: A Single Institution Experience,” British Journal of Cancer, Vol. 81, No. 5, 1999, pp. 841-845.
doi:10.1038/sj.bjc.6690773
|
|
[33]
|
P. J. Sr Loehrer, M. Chen, K. Kim, et al., “Cisplatin, Doxorubicin and Cyclophosphamide Plus Thoracic Radioation Therapy for Limited-Stage Unresectable Thymoma: An Intergroup Trial,” Journal of Clinical Oncology, Vol. 15, No. 9, 1997, pp. 3093-3099.
|
|
[34]
|
“Lung Cancer Evidence-Based Series (EBS) and Practice Guidelines (PG) (Cancer Care Ontario Website).”
http://www.cancercare.on.ca/english/home/toolbox/qualityguidelines/diseasesite/lung-ebs/
|
|
[35]
|
T. Evans and T. J. Lynch, “Role of Chemotherapy in the Management of Advanced Thymic Tumors,” Seminars in Thoracic and Cardiovascular Surgery, Vol. 17, No. 1, 2005, pp. 41-50. doi:10.1053/j.semtcvs.2004.11.003
|
|
[36]
|
G. Giaccone, A. Ardizzoni, A. Kirkpatrick, et al., “Cisplatin and Etoposide Combination Chemotherapy for Locally Advanced or Metastatic Thymoma. A phase II Study of the European Organisation for Research and Treatment of Cancer Lung Cancer Cooperative Group,” Journal of Clinical Oncology, Vol. 14, No. 3, 1996, pp. 814-820.
|
|
[37]
|
P. J. Sr Loehrer, K. Kim, S. C. Aisner, et al., “Cisplatin Plus Doxorubicin plus Cyclophosphamide in Metastatic or Recurrent Thymoma: Final Results of an Intergroup Trial. The Eastern Cooperative Oncology Group, SouthWest Oncology Group, and Southeastern Cancer Study Group,” Journal of Clinical Oncology, Vol. 12, No. 6, 1994, pp. 1164-1168.
|
|
[38]
|
R. J. Kelly, I. Petrini, A. Rajan, Y. Wang and G. Giaccone, “Thymic Malignancies: From Clinical Management to Targeted Therapies,” Journal of Clinical Oncology, Vol. 29, No. 36, 2011, pp. 4820-4827.
doi:10.1200/JCO.2011.36.0487
|
|
[39]
|
N. Girard, RohitLal, P. Loehrer, et al., “Chemotherapy Definitions and Policies for Thymic Malignancies,” Journal of Thoracic Oncology, Vol. 6, No. 7, 2011, pp. S1749-S1755. doi:10.1097/JTO.0b013e31821ea5f7
|
|
[40]
|
A. M. Cimpean, M. Raica, S. Encica, et al., “Immunohistochemical Expression of Vascular Endothelial Growth Factor A (VEGF) and Its Receptors (VEGFR1,2) in Normal and Pathological Conditions of the Human Thymus,” Annals of Anatomy, Vol. 190, No. 3, 2008, pp. 238-245.
doi:10.1016/j.aanat.2007.05.003
|
|
[41]
|
H. Sasaki, H. Yukiue, Y. Kobayashi, et al., “Elevated Serum Vascular Endothelial Growth Factor and Basis Fibroblast Growth Factor Levels in Patients with Thymic Epithelial Neoplasms,” Surgery Today, Vol. 31, No. 11, 2001, pp. 1038-1040. doi:10.1007/s005950170021
|
|
[42]
|
M. Tomita, Y. Matsuzaki, M. Edagawa, et al., “Correlation between Tumor Angiogenesis and Invasiveness in Thymic Epithelial Tumors,” The Journal of Thoracic and Cardiovascular Surgery, Vol. 124, No. 3, 2002, pp. 493498. doi:10.1067/mtc.2002.124389
|
|
[43]
|
G. Giaccone, A. Rajan, A. Berman, et al., “Phase II Study of Belinostat in Patients with Recurrent or Refractory Advanced Thymic Epithelial Tumors,” Journal of Clinical Oncology, Vol. 29, No. 15, 2011, pp. 2052-2059.
doi:10.1200/JCO.2010.32.4467
|
|
[44]
|
C. Kirkove, J. Berghmans, H. Noel, et al., “Dramatic Response of Recurrent Invasive Thymoma to High Doses of Corticosteroids,” Clinical Oncology, Vol. 4, No. 1, 1992, pp. 64-66. doi:10.1016/S0936-6555(05)80783-6
|
|
[45]
|
C. Craven, P. K. Reddy, S. P. Ringel, et al., “Effect of Corticosteroids on the Thymus in Myasthenia Gravis,” Muscle Nerve, Vol. 4, No. 5, 1981, pp. 425-428.
doi:10.1002/mus.880040512
|
|
[46]
|
T. Reisine and G. I. Bell, “Molecular Biology of Somatostatin Receptors,” Endocrine Reviews, Vol. 16, No. 4, 1995, pp. 427-442.
|
|
[47]
|
P. J. Sr Loehrer, W. Wang, D. H. Johnson, et al., “Octreotide Alone or with Prednisone in Patients with Advanced Thymoma and Thymic Carcinoma: An Eastern Cooperative Oncology Group Phase II Trial,” Journal of Clinical Oncology, Vol. 22, No. 2, 2004, pp. 293-299.
doi:10.1200/JCO.2004.02.047
|
|
[48]
|
N. Girard, J. Teruya-Feldstein, E. C. Payabyab, et al., “Insulin-Like Growth Factor-1 Receptor Expression in Thymic Malignancies,” Journal of Thoracic Oncology, Vol. 5, No. 9, 2010, pp. 1439-1446.
doi:10.1097/JTO.0b013e3181e392a8
|
|
[49]
|
P. Haluska, H. M. Shaw, G. N. Batzel, et al., “Phase I Dose Escalation Study of the Anti-Insulin-Like Growth Factor-I Receptor Monoclonal Antibody CP-751, 871 in Patients with Refractory Solid Tumors,” Clinical Cancer Research, Vol. 13, No. 19, 2007, pp. 5834-5840.
doi:10.1158/1078-0432.CCR-07-1118
|
|
[50]
|
C. Shih, V. J. Chen, L. S. Gosset, et al., “LY231514, a Pyrroro (2,3) Pyrimidine-Based Anti-Folate That Inhibits Multiple Folate-Requiring Enzymes,” Cancer Research, Vol. 57, No. 6, 1997, pp. 1116-1123.
|
|
[51]
|
N. J. Vogelzang, J. J. Rusthoven, J. Symanowski, et al., “Phase III Study of Pemetrexed in Combination with Cisplatin Versus Cisplatin Alone in Patients with Malignant Pleural Mesothelioma,” Journal of Clinical Oncology, Vol. 21, No. 14, 2003, pp. 2636-2644.
doi:10.1200/JCO.2003.11.136
|
|
[52]
|
N. Hanna, F. A. Shepherd, F. V. Fossella, et al., “Randomized Phase III Trial of Pemetrexed versus Docetaxel in Patients with Non-Small-Cell Lung Cancer Previously Treated with Chemotherapy,” Journal of Clinical Oncology, Vol. 22, No. 9, 2004, pp. 1589-1597.
doi:10.1200/JCO.2004.08.163
|
|
[53]
|
G. V. Scagliotti, P. Parikh, J. vonPawel, et al., “Phase III Study Comparing Cisplatin Plus Gemcitabine with Cisplatin Plus Pemetrexed In Chemotherapy-Naive Patients with Advanced-Stage Non-Small-Cell Lung Cancer,” Journal of Clinical Oncology, Vol. 26, No. 21, 2008, pp. 3543-3551. doi:10.1200/JCO.2007.15.0375
|
|
[54]
|
G. V. Scagliotti, N. Hanna, F. Fossella, et al., “The Differential Efficacy of Pemetrexed According to NSCLC Histology: A Review of Two Phase III Studies,” The Oncologist, Vol. 14, No. 3, 2009, pp. 253-263.
doi:10.1634/theoncologist.2008-0232
|
|
[55]
|
R. M. Schultz, V. J. Chen, J. R. Belwely, et al., “Biological Activity of the Multitargetedantifolate, Mta (Ly231514), in Human Cell Lines with Different Resistance Mechanisms to Antifolate Drugs,” Seminars in Oncology, Vol. 26, No. 2 supplement 6, 1999, pp. 68-73.
|
|
[56]
|
E. Giovannetti, V. Mey, S. Nannizzi, et al., “Cellular and Pharmacogenetics Foundation of Synergistic Interaction of Pemetrexed and Gemcitabine in Human Non-SmallCell Lung Cancer Cells,” Molecular Pharmacology, Vol. 68, No. 1, 2005, pp. 110-118.
|
|
[57]
|
P. Ceppi, M. Volante, S. Saviozzi, et al., “Squamous Cell Carcinoma of the Lung Compared with Other Histotypes Shows Higher Messenger RNA and Protein Levels for Thymidylate Synthase,” Cancer, Vol. 107, No. 7, 2006, pp. 1589-1596. doi:10.1002/cncr.22208
|
|
[58]
|
P. Ceppi, M. Volante, A. Ferrero, et al., “Thymidylate Synthase Expression in Gastroenteropancreatic and Pulmonary Neuroendocrine Tumors,” Clinical Cancer Research, Vol. 14, No. 4, 2008, pp. 1059-1064.
doi:10.1158/1078-0432.CCR-07-1513
|
|
[59]
|
P. J. Loehrer, C. T. Yiannoutsos, S. Dropcho, et al., “A Phase II Trial of Pemetrexed in Patients with Recurrent Thymoma or Thymic Carcinoma,” Journal of Clinical Oncology, Vol. 24, No. 18s, 2006.
|